GlassScriptPhysician profile
Connor A Patterson
NPI 1548475189
$6,965.06
in general payments reported to CMS, 2019-2025
27 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $655 · 2021: $446 · 2022: $310 · 2023: $1,193 · 2024: $1,848 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.44 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $679.57 | 2019-2025 | |
| Janssen Biotech, INC. | $662.66 | 2019-2025 | Tremfya |
| Ucb, INC. | $528.35 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $501.76 | 2019-2025 | |
| Lilly USA, LLC | $390.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $368.82 | 2019-2025 | |
| Leo Pharma INC. | $303.59 | 2019-2025 | Adbry |
| Incyte Corporation | $276.04 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $266.78 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $216.50 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $201.27 | 2019-2023 | Libtayo, Dupixent |
| Amgen INC. | $136.60 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $132.41 | 2023-2025 | Sotyktu |
| Celgene Corporation | $122.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $113.22 | 2024-2025 | Zoryve |
| Kerecis Limited | $95.48 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.84 | 2019-2020 | |
| Organon LLC | $63.89 | 2025 | Vtama |
| Genentech USA, INC. | $52.46 | 2019 | |
| Epi Health, LLC | $47.70 | 2019-2020 | |
| Galderma Laboratories, L.P. | $43.03 | 2019-2020 | |
| Almirall LLC | $29.46 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $27.16 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2024 | Spevigo |
| Merz North America, INC. | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.